Universal Beteiligungs und Servicegesellschaft mbH Makes New $2.93 Million Investment in AtriCure, Inc. (NASDAQ:ATRC)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 90,693 shares of the medical device company's stock, valued at approximately $2,926,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.18% of AtriCure at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of ATRC. Ameriprise Financial Inc. bought a new stake in AtriCure in the fourth quarter worth about $295,000. JPMorgan Chase & Co. grew its stake in AtriCure by 43.1% during the fourth quarter. JPMorgan Chase & Co. now owns 365,183 shares of the medical device company's stock valued at $11,160,000 after acquiring an additional 110,039 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in AtriCure by 5.0% during the first quarter. Assenagon Asset Management S.A. now owns 146,096 shares of the medical device company's stock valued at $4,713,000 after acquiring an additional 6,995 shares in the last quarter. GAMMA Investing LLC grew its stake in AtriCure by 9,664.9% during the first quarter. GAMMA Investing LLC now owns 3,613 shares of the medical device company's stock valued at $112,000 after acquiring an additional 3,576 shares in the last quarter. Finally, Sei Investments Co. grew its stake in AtriCure by 6.1% during the fourth quarter. Sei Investments Co. now owns 107,290 shares of the medical device company's stock valued at $3,279,000 after acquiring an additional 6,152 shares in the last quarter. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ATRC has been the subject of a number of recent research reports. Needham & Company LLC boosted their price objective on shares of AtriCure from $44.00 to $45.00 and gave the stock a "buy" rating in a report on Wednesday. BTIG Research set a $54.00 price target on shares of AtriCure in a research note on Wednesday. UBS Group decreased their target price on shares of AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. JMP Securities reissued a "market outperform" rating and set a $60.00 price objective on shares of AtriCure in a report on Wednesday, April 30th. Finally, Wall Street Zen cut shares of AtriCure from a "buy" rating to a "hold" rating in a report on Sunday, June 1st. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $50.89.

AtriCure Trading Down 2.0%

Shares of ATRC traded down $0.69 during midday trading on Friday, hitting $34.41. The stock had a trading volume of 730,309 shares, compared to its average volume of 592,016. AtriCure, Inc. has a 1 year low of $20.20 and a 1 year high of $43.11. The firm has a market cap of $1.70 billion, a PE ratio of -44.69 and a beta of 1.56. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.11 and a quick ratio of 2.88. The stock's 50 day moving average is $32.33 and its 200 day moving average is $34.32.

AtriCure (NASDAQ:ATRC - Get Free Report) last announced its earnings results on Tuesday, July 29th. The medical device company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.13. The business had revenue of $136.14 million for the quarter, compared to the consensus estimate of $130.17 million. AtriCure had a negative net margin of 7.27% and a negative return on equity of 4.21%. The business's revenue for the quarter was up 17.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.17) earnings per share. As a group, analysts forecast that AtriCure, Inc. will post -0.6 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Vinayak Doraiswamy sold 2,500 shares of the firm's stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $33.44, for a total value of $83,600.00. Following the transaction, the insider owned 73,550 shares of the company's stock, valued at $2,459,512. This trade represents a 3.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 3.50% of the stock is owned by corporate insiders.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.